Core Insights - Precigen (PGEN) stock has increased by 185% since early July, primarily due to the FDA approval of its lead asset for Recurrent Respiratory Papillomatosis (RRP) [1] Company Summary - Precigen has received FDA approval for its leading product, which is expected to significantly impact its market position and growth potential [1]